Ameriprise
AKRO

Ameriprise’s Akero Therapeutics AKRO Stock Holding History

Ameriprise’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,100
Closed -$527K – 4074
2025
Q3 		$527K Buy
11,100
+300
+3% +$14.5K ﹤0.01% 3609
2025
Q2 		$576K Buy
+10,800
New +$491K ﹤0.01% 3481

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ameriprise's AKRO Position: Q4 2025 in Review

Ameriprise sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 291,593 shares — an estimated $13.8M sold.

Ameriprise first reported a position in AKRO in Q3 2022 and held it in 11 quarters. The position peaked at $14.6M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Ameriprise reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 291,593 Akero Therapeutics shares in Q4 2025, an estimated $13.8M.
  • Ameriprise first reported a position in Akero Therapeutics in Q3 2022 and held it in 11 quarters.
  • Ameriprise's Akero Therapeutics position peaked at $14.6M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.